Login / Signup

Diffuse large B-cell lymphoma: A consensus practice statement from the Australasian Lymphoma Alliance.

Joel C WightNada HamadB A CampbellMatthew KuK LeeH RoseT ArmytageM LatimerH P LeeSze Ting LeeMichael J DickinsonR KhorE Verner
Published in: Internal medicine journal (2021)
Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma subtype, accounting for 30-40% of lymphoma diagnoses. Though aggressive, cure is achievable in approximately 60% of cases with primary chemo-immunotherapy, and in a further substantial minority by salvage therapy and autologous stem cell transplantation. Despite promising activity in early phase clinical trials, no intensified or novel treatment regimen has improved outcomes over R-CHOP21 in randomised studies. However, there remain several areas of controversy including the most appropriate prognostic markers, CNS prophylaxis and the optimal treatment for patients with high-risk disease. This position statement presents an evidence-based synthesis of the literature for application in Australasian practice. This article is protected by copyright. All rights reserved.
Keyphrases